Padua Prediction Score for VTE Risk in Thoracic Surgery Patients
Launched by AL-NAHRAIN UNIVERSITY · Dec 10, 2024
Trial Information
Current as of April 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
Venous thromboembolism (VTE) is a significant cause of morbidity and mortality, comprising conditions like deep vein thrombosis (DVT) and pulmonary embolism (PE). Hospitalized patients are particularly vulnerable to VTE due to factors such as prolonged immobility, surgical procedures, and preexisting comorbidities.
To address this risk, tools like the Padua Prediction Score (PPS) have been developed. PPS is a validated scoring system that uses clinical and demographic criteria to categorize patients as high- or low-risk for VTE, allowing healthcare providers to tailor prophylactic measures...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who have undergone preoperative Padua Prediction Score assessment.
- • Inpatients with a hospital stay over 3 days
- • Written informed consent obtained from patients or their legal guardians.
- • Availability for postoperative follow-up to assess outcomes like LEVT development or related complications.
- Exclusion Criteria:
- • Preexisting LEVT or pulmonary embolism.
- • Severe Coagulopathy: Patients with inherited or acquired bleeding disorders (e.g., hemophilia, advanced liver disease).
- • receiving any anticoagulation therapy for any reason.
- • patients who did not undergo a postoperative D-dimer test.
- • Incomplete Data: missing essential clinical or laboratory data.
- • Pregnancy: pregnant women or those within six weeks postpartum.
- • Noncompliance: Patients unwilling or unable to adhere to study follow-up protocols.
Trial Officials
Yaser aamer Eisa Alhaibi, Assistant professor
Study Director
College Of Medicine - Nahrain University
About Al Nahrain University
Al-Nahrain University is a leading academic institution dedicated to advancing medical research and education in Iraq. With a focus on innovative clinical trials, the university aims to enhance healthcare outcomes through rigorous scientific investigation and collaboration with local and international partners. Its commitment to ethical research practices and adherence to regulatory standards positions Al-Nahrain University as a pivotal contributor to the development of new therapeutic interventions and the overall improvement of public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baghdad, Kadhimiya, Iraq
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported